|
|
|
Volumn 4, Issue 1, 2002, Pages 72-75
|
|
Technology evaluation: BL22, NCl
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMINOTRANSFERASE;
BL 22;
CD22 ANTIGEN;
CLADRIBINE;
CREATININE;
DISULFIDE;
IMMUNOTOXIN;
INFLIXIMAB;
LYMPHOCYTE ANTIBODY;
PSEUDOMONAS EXOTOXIN;
ROFECOXIB;
SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;
UNCLASSIFIED DRUG;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ARTICLE;
B CELL LYMPHOMA;
CANCER CENTER;
CANCER IMMUNOTHERAPY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG DISTRIBUTION;
DRUG ELIMINATION;
DRUG HALF LIFE;
EDEMA;
FEMALE;
GENE FUSION;
HAIRY CELL LEUKEMIA;
HEMOLYTIC UREMIC SYNDROME;
HUMAN;
HYPOALBUMINEMIA;
MOUSE;
MYALGIA;
NAUSEA;
NONHUMAN;
PHASE 1 CLINICAL TRIAL;
SIDE EFFECT;
ANIMALS;
ANTIBODIES;
CLINICAL TRIALS;
ENTEROTOXINS;
HUMANS;
IMMUNOTHERAPY;
IMMUNOTOXINS;
LEUKEMIA, B-CELL;
LEUKEMIA, HAIRY CELL;
LYMPHOMA, B-CELL;
MICE;
NEOPLASMS;
PSEUDOMONAS;
ANIMALIA;
PSEUDOMONAS;
|
|
EID: 0036083072
PISSN: 14648431
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (8)
|
|
References (0)
|
